[go: up one dir, main page]

WO2004030629A3 - Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation - Google Patents

Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2004030629A3
WO2004030629A3 PCT/US2003/031153 US0331153W WO2004030629A3 WO 2004030629 A3 WO2004030629 A3 WO 2004030629A3 US 0331153 W US0331153 W US 0331153W WO 2004030629 A3 WO2004030629 A3 WO 2004030629A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurokinin
tachykinin
disorders
methods
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/031153
Other languages
English (en)
Other versions
WO2004030629A2 (fr
Inventor
Oren Becker
Dale S Dhanoa
Silvia Noiman
Anurag Sharadendu
Venkitasamy Kesavan
Pradyumna Mohanty
Yael Marantz
Ori Kalid
Dongli Chen
Sacham Sharon
Raphael Nudelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PREDIX PHARMACEUTICALS
Original Assignee
PREDIX PHARMACEUTICALS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PREDIX PHARMACEUTICALS filed Critical PREDIX PHARMACEUTICALS
Priority to AU2003277215A priority Critical patent/AU2003277215A1/en
Publication of WO2004030629A2 publication Critical patent/WO2004030629A2/fr
Publication of WO2004030629A3 publication Critical patent/WO2004030629A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des antagonistes du récepteur de la tachynine, la famille de la famille de récepteurs de la tachynine comprenant la substance P des neurokinines (SP), de la neurokinine A. et de la neurokinine B et des neuropeptides qui sont largement répartis dans le système nerveux central et périphérique. La présente invention décrit de nouveaux antagonistes de la neurokinine représentés par les formule I-IV, et leur synthèse et utilisations pour le traitement de maladies provoquées directement ou indirectement par les récepteurs de la tachynine. De telles conditions comprennent les troubles du système nerveux central tels que l'anxiété, la douleur, la dépression, le vomissement, par exemple le vomissement induit par la chimiothérapie anticancéreuse, les maladie respiratoires et intestinales inflammatoires et d'autre troubles gastriques, l'asthme, la schizophrénie, les maladies ophtalmiques telles que le glaucome, l'hypertension oculaire, la lésion neuronale, l'accident vasculaire cérébral, les troubles cardiaques, le psoriasis et la migraine. L'invention a également trait à des procédés de préparation et de nouveaux intermédiaires et de sels pharmaceutiques desdits antagonistes.
PCT/US2003/031153 2002-10-01 2003-09-30 Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation Ceased WO2004030629A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003277215A AU2003277215A1 (en) 2002-10-01 2003-09-30 Novel neurokinin antagonists and methods of use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US41504502P 2002-10-01 2002-10-01
US60/415,045 2002-10-01
US42518702P 2002-11-08 2002-11-08
US42513002P 2002-11-08 2002-11-08
US42518602P 2002-11-08 2002-11-08
US60/425,130 2002-11-08
US60/425,186 2002-11-08
US60/425,187 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004030629A2 WO2004030629A2 (fr) 2004-04-15
WO2004030629A3 true WO2004030629A3 (fr) 2004-11-04

Family

ID=32074647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031153 Ceased WO2004030629A2 (fr) 2002-10-01 2003-09-30 Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2003277215A1 (fr)
WO (1) WO2004030629A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
CA2727055C (fr) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. Pyridoindoles (1-azinone)-substitues en tant qu'antagonistes mch
US8114894B2 (en) 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2011003021A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azabicycloalcane-indoles et azabicycloalcane-pyrrolo-pyridines substitués par azinone, leurs procédés de fabrication et leur utilisation
WO2011003012A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
EP2448585B1 (fr) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Antagonistes de mch-1 d azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2018130123A1 (fr) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 Composé pentacyclique utilisé en tant que régulateur sélectif du récepteur des œstrogènes et son utilisation
CN112955433A (zh) 2017-09-08 2021-06-11 赛伯克斯股份有限公司 选择性抑制β-葡糖醛酸糖苷酶和减轻与药物治疗引起的腹泻有关的副作用的化合物、组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981029, Database accession no. 2003:1788360 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981030, Database accession no. 2003:1788092 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981031, Database accession no. 2002:2019309 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981032, Database accession no. 2003:1788391 *

Also Published As

Publication number Publication date
AU2003277215A8 (en) 2004-04-23
AU2003277215A1 (en) 2004-04-23
WO2004030629A2 (fr) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2004014850A3 (fr) Aminopyrimidines substituees utilisees en tant qu'agonistes de la neurokinine
WO2004030629A3 (fr) Nouveaux antagonistes de la neurokinine et leurs procedes d'utilisation
WO2004069794A3 (fr) Nouveaux composes d'arylpiperazinyle
WO2004089312A3 (fr) Nouveaux composes de piperidinylamino-thieno[2,3-d] pyrimidine
JP5705249B2 (ja) 置換されたピリジン誘導体
DE69633607T2 (de) Piperidinderivate mit tachykinin-antagonistischer wirkung
DE69628035T2 (de) In 4-stellung substituierte piperidin-analoge und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
DE60027011T2 (de) Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
CN103889968A (zh) 氨基苯并二氢吡喃、氨基苯并二氢噻喃及氨基-1,2,3,4-四氢喹啉衍生物，包含这些化合物的药用组合物，及其在治疗中的用途
WO2007063385A3 (fr) Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
UA88719C2 (ru) Антагонисты рецепторов гистамина-3
MA27847A1 (fr) Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle.
CN103180299A (zh) 四氢化萘和二氢化茚衍生物、含其的药物组合物及其在治疗中的用途
EP2468732B1 (fr) 1H-quinazoline-2,4-diones
TW201605840A (zh) 胺基唍、胺基硫唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
CN104011028A (zh) N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
HUE031661T2 (en) Combinations of serotonin receptor agonists for the treatment of movement disorders
CN104955826B (zh) 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
Manera et al. Rational design, synthesis, and pharmacological properties of new 1, 8-naphthyridin-2 (1 H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists
EP0740658B1 (fr) Derives n-substitues d'azabicycloheptane utilises, par exemple, comme neuroleptiques
BR0309778A (pt) Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2b
EA200701345A1 (ru) Производные триазолона, тетразолона и имидазолона для применения в качестве антагонистов альфа-2с-адренорецептора

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP